NewAmsterdam Pharma Company NV [NASDAQ: NAMS] traded at a high on Thursday, posting a 1.93 gain after which it closed the day’ session at $16.34.
The results of the trading session contributed to over 277248 shares changing hands. Over the past one week, the price volatility of NewAmsterdam Pharma Company NV stands at 7.76% while the volatility over the past one month is 8.58%.
The market cap for NAMS stock reached $1.79 billion, with 108.06 million shares outstanding and 61.06 million shares in the current float. Compared to the average trading volume of 1.03M shares, NAMS reached a trading volume of 277248 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about NewAmsterdam Pharma Company NV [NAMS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NAMS shares is $44.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NAMS stock is a recommendation set at 1.18. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for NewAmsterdam Pharma Company NV shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 30, 2024. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on May 15, 2024, representing the official price target for NewAmsterdam Pharma Company NV stock. Previously, the target price had yet another raise to $35, while Scotiabank analysts kept a Sector Outperform rating on NAMS stock.
The Average True Range (ATR) for NewAmsterdam Pharma Company NV is set at 1.43, with the Price to Sales ratio for NAMS stock in the period of the last 12 months amounting to 39.39. The Price to Book ratio for the last quarter was 2.33, with the Price to Cash per share for the same quarter was set at 7.60.
How has NAMS stock performed recently?
NewAmsterdam Pharma Company NV [NAMS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.66. With this latest performance, NAMS shares dropped by -30.79% in over the last four-week period, additionally sinking by -14.00% over the last 6 months – not to mention a drop of -16.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NAMS stock in for the last two-week period is set at 35.87, with the RSI for the last a single of trading hit 37.69, and the three-weeks RSI is set at 36.83 for NewAmsterdam Pharma Company NV [NAMS]. The present Moving Average for the last 50 days of trading for this stock 20.12, while it was recorded at 15.99 for the last single week of trading, and 19.96 for the last 200 days.
NewAmsterdam Pharma Company NV [NAMS]: Deeper insight into the fundamentals
NewAmsterdam Pharma Company NV’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.08 and a Current Ratio set at 8.08.
Earnings analysis for NewAmsterdam Pharma Company NV [NAMS]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NAMS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for NewAmsterdam Pharma Company NV go to 17.99%.
Insider trade positions for NewAmsterdam Pharma Company NV [NAMS]
There are presently around $99.34%, or 99.69%% of NAMS stock, in the hands of institutional investors. The top three institutional holders of NAMS stocks are: FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with ownership of 12.23 million shares, which is approximately 12.9097%. FCPM III SERVICES B.V., holding 11.83 million shares of the stock with an approximate value of $$227.28 million in NAMS stocks shares; and FCPM III SERVICES B.V., currently with $$201.2 million in NAMS stock with ownership which is approximately 11.0587%.
